We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Infection in Indian Neonates - Phase II Probiotics Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00518596
First Posted: August 21, 2007
Last Update Posted: June 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Global Network for Women's and Children's Health Research
Bill and Melinda Gates Foundation
John E. Fogarty International Center (FIC)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Dental and Craniofacial Research (NIDCR)
National Cancer Institute (NCI)
RTI International
All India Institute of Medical Sciences, New Delhi
TN Medical College, Mumbai
Department of Health and Family Welfare, Orissa
SCB Medical College, Cuttack
Capital Hospital, Bhubaneswar
Ispat General Hospital, Rourkela
Kalinga Hospital, Bhubaneswar
University of Maryland
Information provided by (Responsible Party):
NICHD Global Network for Women's and Children's Health
  Purpose
India, with one of the world's largest populations, continues to struggle with extremely high infant and neonatal mortality rates. Neonatal infection (sepsis) now accounts for 50 percent of deaths among community-born (and 20 percent of mortality among hospital-born) infants. This study is the first phase of a multi-phase project investigating interventions to prevent neonatal infection in India.

Condition Intervention Phase
Sepsis Dietary Supplement: Probiotic supplementation (Lactobacillus plantarum) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Prevention of Infection in Indian Neonates - Phase II Probiotics Study

Resource links provided by NLM:


Further study details as provided by NICHD Global Network for Women's and Children's Health:

Primary Outcome Measures:
  • Colonizing ability of L. plantarum in Indian neonates after 5-7 days of administration. [ Time Frame: 28 days ]
  • Clinical safety (including sepsis and death) and tolerance of a daily administration of oral L. plantarum probiotic supplement when used in healthy full-term neonates. [ Time Frame: 28 days ]
  • Changes in stool microfloral patterns with 5-7 day administration of L. plantarum supplement.

Secondary Outcome Measures:
  • Feasibility of the future community study (consent and retention rates, completeness of stool sampling, ability to complete the study in the home for infants discharged early).

Enrollment: 284
Study Start Date: July 2005
Study Completion Date: August 2006
Arms Assigned Interventions
Experimental: Probiotic Arm
Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
Dietary Supplement: Probiotic supplementation (Lactobacillus plantarum)
GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Other Name: Gastroplan
Placebo Comparator: Control Arm
Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
Dietary Supplement: Probiotic supplementation (Lactobacillus plantarum)
GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
Other Name: Gastroplan

Detailed Description:
Phase II is a hospital based intervention (n = 297 infants) measuring the colonizing ability, safety, and tolerance of a probiotic supplement, Lactobacillus plantarum in the neonatal gut. Newborn infants ≥ 35 weeks of gestation will be randomized to receive either L. plantarum preparations (containing 109 organisms) or placebo preparations orally once a day for the first 7 days of life. The final stage of the project will be a community-based randomized double-blind placebo-controlled trial of L. plantarum enrolling over 8,000 newborns to examine the efficacy of probiotic supplementation in reducing neonatal infection in Indian neonates.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 72 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Infants ≥ 35 weeks and ≥1800g born in the hospital
  • Infants > 12 hours and < 72 hours of age at enrollment
  • Infants likely to be hospitalized for 5-7 days without antibiotic treatment
  • Informed consent by one parent or guardian
  • Infants begun breastfeeding

Exclusion Criteria:

  • Antibiotic therapy prior to enrollment
  • Evidence or suspicion of clinical sepsis before randomization
  • Inability (as determined by the physician) to tolerate oral feeding of study supplement
  • Presence of major congenital anomalies
  • Infant's home is >30km away from hospital A major congenital anomaly is defined as any malformation that is felt to be life-threatening or that requires surgical intervention. If the medical officer is uncertain whether an anomaly is life-threatening, he/she should not enroll the infant.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00518596


Locations
India
Capital Hospital
Bhubaneswar, Orissa, India
Kalinga Hospital
Bhubaneswar, Orissa, India
Ispat General Hospital
Rourkela, Orissa, India
Sponsors and Collaborators
NICHD Global Network for Women's and Children's Health
Global Network for Women's and Children's Health Research
Bill and Melinda Gates Foundation
John E. Fogarty International Center (FIC)
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Dental and Craniofacial Research (NIDCR)
National Cancer Institute (NCI)
RTI International
All India Institute of Medical Sciences, New Delhi
TN Medical College, Mumbai
Department of Health and Family Welfare, Orissa
SCB Medical College, Cuttack
Capital Hospital, Bhubaneswar
Ispat General Hospital, Rourkela
Kalinga Hospital, Bhubaneswar
University of Maryland
Investigators
Principal Investigator: Pinaki Panigrahi, M.D. University of Maryland
  More Information

Additional Information:
Responsible Party: NICHD Global Network for Women's and Children's Health
ClinicalTrials.gov Identifier: NCT00518596     History of Changes
Other Study ID Numbers: GN 07 Phase II
U01HD040574 ( U.S. NIH Grant/Contract )
R01HD053719 ( U.S. NIH Grant/Contract )
First Submitted: August 20, 2007
First Posted: August 21, 2007
Last Update Posted: June 15, 2017
Last Verified: June 2017

Keywords provided by NICHD Global Network for Women's and Children's Health:
Neonatal
Sepsis
Global Network
Probiotics
India
International
Maternal and child health

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes